Circulating tumor DNA to direct adjuvant immunotherapy across mismatch repair-deficient solid tumors

医学 循环肿瘤DNA 内科学 肿瘤科 微小残留病 免疫疗法 神秘的 彭布罗利珠单抗 前瞻性队列研究 佐剂 种系突变 癌症 原发性肿瘤 突变 肿瘤 封锁 胃肠病学 切除术 抗体 循环肿瘤细胞 安慰剂 辅助治疗 临床试验 临床意义 外科 化疗 疾病 临床研究阶段
作者
Y.Y. Janjigian,M.A. Lumish,M.B. Foote,F. Socolow,E. Perissinotto,M. Darmofal,M. Madwed,M. Segal,A. Yaqubie,M. Capanu,J.F. Chou,S.B. Maron,G.Y. Ku,L.B. Saltz,J. Garcia-Aguilar,M.R. Weiser,J.A. Konner,R. Guo,V.E. Strong,E. Jewell
出处
期刊:Annals of Oncology [Elsevier BV]
标识
DOI:10.1016/j.annonc.2026.11.005
摘要

BACKGROUND: Detection of circulating tumor DNA (ctDNA) harboring mutations that match those identified in resected tumor tissue signals occult residual disease after curative-intent surgery. Such patients are considered minimal residual disease (MRD)-positive and at high risk for recurrence and death. Few studies have shown that therapeutic intervention can alter recurrence risk in MRD-positive patients. We evaluated whether PD-1 blockade could reduce recurrence in MRD-positive patients with mismatch repair-deficient (dMMR) tumors after curative-intent resection regardless of tumor site of origin. PATIENTS AND METHODS: We initiated a prospective phase II interventional study in patients who had undergone curative-intent resection of early-stage dMMR tumors from any anatomic site. Postoperative MRD status was assessed by first identifying those patients who had detectable ctDNA and then confirming the ctDNA relevance to MRD by matching mutations detected in ctDNA to somatic mutations detected in resected tumor tissue. Confirmed MRD-positive patients received 6 months of PD-1 blockade and were evaluated for ctDNA clearance and 24-month recurrence-free survival (RFS). MRD-negative patients underwent observation. RESULTS: We screened 184 patients with early-stage dMMR solid tumors after curative resection and tumor sequencing with ctDNA testing for MRD assessment. Twenty-three patients (12.5%) were MRD-positive; after excluding one assigned to placebo and three with synchronous radiographic disease, 19 were eligible. Six developed recurrences before pembrolizumab initiation despite being disease-free at enrollment. The remaining 13 MRD-positive patients received 6 months of PD-1 blockade. ctDNA clearance at 6 months was achieved in 11 of 13 patients (85%). Five treated patients (38%) developed recurrence during follow-up. Median follow-up for the MRD-positive patients was 59 months (95% CI: 52-NR). Among 152 MRD-negative patients managed with observation, 14 (9%) developed recurrence during follow-up; 2-year RFS was 92%. CONCLUSIONS: These findings provide evidence that ctDNA-guided adjuvant therapy may offer clinical benefit in dMMR tumors regardless of tissue of origin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被Hase采纳,获得10
刚刚
ljlcyx发布了新的文献求助10
刚刚
1秒前
1秒前
2秒前
2秒前
2秒前
英姑的应助被lm采纳,获得10
2秒前
哈哈镜阿姐完成签到,获得积分10
3秒前
XXF完成签到,获得积分10
4秒前
科目三的应助被张智磊采纳,获得10
4秒前
5秒前
xiaolizi发布了新的文献求助30
6秒前
高兴绿柳完成签到 ,获得积分10
7秒前
SciGPT的应助被make217采纳,获得10
8秒前
李半斤发布了新的文献求助10
8秒前
wzppp发布了新的文献求助10
8秒前
谱云发布了新的文献求助10
9秒前
啊啊啊完成签到,获得积分10
11秒前
11秒前
搜集达人的应助被疯狂硕士采纳,获得10
12秒前
wzppp完成签到,获得积分10
12秒前
努力努力再努力完成签到,获得积分10
13秒前
15秒前
zj完成签到,获得积分10
16秒前
16秒前
16秒前
落雪无痕完成签到,获得积分10
17秒前
18秒前
完美世界的应助被XiaoMu采纳,获得10
19秒前
hang完成签到,获得积分10
19秒前
领导范儿的应助被ayzzdbr采纳,获得10
19秒前
TTT完成签到,获得积分10
20秒前
20秒前
kun完成签到,获得积分10
20秒前
21秒前
faye完成签到,获得积分10
21秒前
谭代涛发布了新的文献求助10
22秒前
syvshc的应助被AA采纳,获得10
22秒前
zzzbn完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241